We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes
US biotech group is among coronavirus vaccine makers struggling with reduced demand post-pandemic
From India to Britain, we have always managed to get in the way of our own inventiveness
A demonised elite produced vaccines and furloughs while a supposedly rebellious public mostly followed the rules
Noubar Afeyan says court rulings on abortion pills and access to healthcare undermine efforts to combat diseases
European health officials have advocated portfolio diversity to help fight different variants
Covid vaccine maker is sitting on $18bn and embarking on a host of ambitious projects
Revamp that would cut drugmakers’ years of market exclusivity meets fierce opposition from sector
Proposal for compulsory licensing risks ire of pharma groups keen to protect patents and revenue
NHS ‘in limbo’ after Royal College of Nursing calls for 48-hour walkout affecting critical care
Easier access to NHS records will save lives — but health executives must make their case to the public
Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall
Central American nation was one of Taipei’s last partners in Washington’s backyard
Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots
Health secretary confirms acceptance of advice from expert committee to ‘bridge the gap’ to autumn
Fifty organisations form coalition to counter dangerous falsehoods and rebuild trust in science
Employers advised they need to offer more time and flexibility compared with other illnesses
Pharma group is launching 19 drugs over the next 18 months to counteract a sharp fall in sales from pandemic highs
Manufacturers showed during the pandemic that they can deliver low-cost treatments at scale
Pharma group hopes for approval of mRNA vaccine for booster shots
Pascal Soriot criticises pricing agreement with UK health service
UK biotech racing to keep antibody up to date with latest variants
Shortage of doctors with university posts is putting health service on ‘dangerous precipice’
Short-termism and suspicion in parts of government risk our valuable future in precision medicine
Officials row with Pfizer over price as villages struggle to obtain antiviral medication
International Edition
